[
  {
    "ts": "2026-01-23T07:16:14+00:00",
    "headline": "Will Licensing Novavax’s Matrix-M Adjuvant Reshape Pfizer’s (PFE) Vaccine Platform Strategy?",
    "summary": "Earlier in January 2026, Novavax announced a non-exclusive license and option agreement granting Pfizer worldwide rights to use its Matrix-M adjuvant in vaccine products for up to two infectious disease areas, in return for a US$30 million upfront payment plus potential milestones and royalties. The deal effectively lets Pfizer plug a proven third-party adjuvant into its own vaccine platforms while keeping full control over development, manufacturing, and commercialization decisions. With...",
    "url": "https://finance.yahoo.com/news/licensing-novavax-matrix-m-adjuvant-071614596.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "8ae60fa7-6157-37ca-a112-b0f88492e975",
      "content": {
        "id": "8ae60fa7-6157-37ca-a112-b0f88492e975",
        "contentType": "STORY",
        "title": "Will Licensing Novavax’s Matrix-M Adjuvant Reshape Pfizer’s (PFE) Vaccine Platform Strategy?",
        "description": "",
        "summary": "Earlier in January 2026, Novavax announced a non-exclusive license and option agreement granting Pfizer worldwide rights to use its Matrix-M adjuvant in vaccine products for up to two infectious disease areas, in return for a US$30 million upfront payment plus potential milestones and royalties. The deal effectively lets Pfizer plug a proven third-party adjuvant into its own vaccine platforms while keeping full control over development, manufacturing, and commercialization decisions. With...",
        "pubDate": "2026-01-23T07:16:14Z",
        "displayTime": "2026-01-23T07:16:14Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QSfydsi7Q.1zNEN99DbEyw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hi2p7oczHh8yTJraqZcczg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/licensing-novavax-matrix-m-adjuvant-071614596.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/licensing-novavax-matrix-m-adjuvant-071614596.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NVAX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-23T15:20:00+00:00",
    "headline": "The Top Stock to Buy With $30 for 2026",
    "summary": "It's a great opportunity to \"buy low.\"",
    "url": "https://www.fool.com/investing/2026/01/23/the-top-stock-to-buy-with-30-for-2026/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "decfd36c-c4d2-32c1-af66-24a701859a90",
      "content": {
        "id": "decfd36c-c4d2-32c1-af66-24a701859a90",
        "contentType": "STORY",
        "title": "The Top Stock to Buy With $30 for 2026",
        "description": "",
        "summary": "It's a great opportunity to \"buy low.\"",
        "pubDate": "2026-01-23T15:20:00Z",
        "displayTime": "2026-01-23T15:20:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/673be218b425a3f969934c44dce39cd4",
          "originalWidth": 1400,
          "originalHeight": 828,
          "caption": "A pharmacist talking to a patient. ",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kddSpVhM9huTHd.Fl85sHQ--~B/aD04Mjg7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/673be218b425a3f969934c44dce39cd4.cf.webp",
              "width": 1400,
              "height": 828,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2ryBz4p_8tCpd0cxaBYK1A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/673be218b425a3f969934c44dce39cd4.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/01/23/the-top-stock-to-buy-with-30-for-2026/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/top-stock-buy-30-2026-152000612.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-23T13:36:00+00:00",
    "headline": "Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q4 Earnings",
    "summary": "LLY's oncology drugs, led by Verzenio and new launches, are set to support upcoming Q4 results as investor focus broadens beyond GLP-1s.",
    "url": "https://finance.yahoo.com/news/heres-eli-lillys-oncology-drugs-133600753.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "a902c7fb-d30a-336e-bdf1-87eb5d237bda",
      "content": {
        "id": "a902c7fb-d30a-336e-bdf1-87eb5d237bda",
        "contentType": "STORY",
        "title": "Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q4 Earnings",
        "description": "",
        "summary": "LLY's oncology drugs, led by Verzenio and new launches, are set to support upcoming Q4 results as investor focus broadens beyond GLP-1s.",
        "pubDate": "2026-01-23T13:36:00Z",
        "displayTime": "2026-01-23T13:36:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/3c8c5ffebabb5a0d6f7bffb8eb41c523",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Zg3ykhh14An2bfVuUvzbag--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3c8c5ffebabb5a0d6f7bffb8eb41c523.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8KeSNQWO2yQtdmAEk3F_Nw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3c8c5ffebabb5a0d6f7bffb8eb41c523.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/heres-eli-lillys-oncology-drugs-133600753.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/heres-eli-lillys-oncology-drugs-133600753.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]